MDT

83.88

-0.64%↓

VEEV

226.14

-0.65%↓

A

106

-0.63%↓

WBA

10.98

-0.36%↓

CHE

557.17

+1.84%↑

MDT

83.88

-0.64%↓

VEEV

226.14

-0.65%↓

A

106

-0.63%↓

WBA

10.98

-0.36%↓

CHE

557.17

+1.84%↑

MDT

83.88

-0.64%↓

VEEV

226.14

-0.65%↓

A

106

-0.63%↓

WBA

10.98

-0.36%↓

CHE

557.17

+1.84%↑

MDT

83.88

-0.64%↓

VEEV

226.14

-0.65%↓

A

106

-0.63%↓

WBA

10.98

-0.36%↓

CHE

557.17

+1.84%↑

MDT

83.88

-0.64%↓

VEEV

226.14

-0.65%↓

A

106

-0.63%↓

WBA

10.98

-0.36%↓

CHE

557.17

+1.84%↑

Search

PTC Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

49.51 0.06

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

47.77

Max

49.97

Schlüsselkennzahlen

By Trading Economics

Einkommen

41M

-66M

Verkäufe

16M

213M

EPS

-0.342

Gewinnspanne

-30.907

Angestellte

939

EBITDA

3M

-47M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+34.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

286M

3.8B

Vorheriger Eröffnungskurs

49.45

Vorheriger Schlusskurs

49.51

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

PTC Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Dez. 2024, 12:47 UTC

Wichtige Markttreiber

PTC Therapeutics Shares Jump on Pact With Novartis

Peer-Vergleich

Kursveränderung

PTC Therapeutics Inc Prognose

Kursziel

By TipRanks

34.61% Vorteil

12-Monats-Prognose

Durchschnitt 66.7 USD  34.61%

Hoch 113 USD

Tief 50 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für PTC Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

6

Buy

5

Halten

1

Sell

Technischer Score

By Trading Central

48.255 / 49.95Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.